We also observed reductions in expression of PD-L1 mRNA in several NSCLC cell lines with endogenous KRAS mutations following treatment with NAC, reduced glutathione, or MK2 inhibitor III (Figure S5D), although we noted some heterogeneity in response between the four cell lines tested. Here, KRAS is linked to non-small cell lung carcinoma.